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ABSTRACT
Multiple factors critical to the effectiveness of academic
phase I cancer programs were assessed among 16 academic
centers in the U.S. Successful cancer centers were defined as
having broad phase I and I/II clinical trial portfolios, multiple
investigator-initiated studies, and correlative science. The
most significant elements were institutional philanthropic
support, experienced clinical research managers, robust
institutional basic research, institutional administrative
efforts to reduce bureaucratic regulatory delays, phase I nav-
igators to inform patients and physicians of new studies, and
a large cancer center patient base. New programs may bene-
fit from a separate stand-alone operation, but mature phase
I programs work well when many of the activities are trans-
ferred to disease-oriented teams. The metrics may be useful
as a rubric for new and established academic phase I pro-
grams. The Oncologist 2017;22:369–374
INTRODUCTION
Phase I cancer clinical trials evaluate investigational agents
being used for the first time in humans. In the twentieth cen-
tury, phase I studies were designed to define the relationship
of agent dose and schedule to toxicities. Interpatient dose esca-
lation and alternate schedules were examined. Maximal toler-
ated dose (MTD), recommended phase II dose (RP2D), dose-
limiting toxicities (DLTs), and pharmacokinetics (PK) were
assessed. This approach was nonspecific as most anticancer
agents were cytotoxic drugs that inhibited DNA synthesis or
mitotic spindles targeting cell proliferation [1], and higher doses
were associated with a narrow therapeutic index—greater tox-
icity and efficacy. However, cancer therapeutics in the twenty-
first century has focused on the introduction of targeted agents
that specifically target tumor antigens or modify tumor, stroma,
or immune pathways. These new agents may not require
achievement of MTD or DLT to achieve maximal antitumor effi-
cacy. Instead, lower doses sufficient tomodulate the target opti-
mally may yield maximal therapeutic gain. Consequently, recent
phase I trials include dose selection, correlative assessments
of potential tumor biomarkers, pharmacodynamics, and/or
metabolic imaging to demonstrate proof-of-mechanism. Expan-
sion cohorts of patients are added to better define toxicities,
drug distribution and metabolism, mechanism of action, and
preliminary evidence of drug efficacy in specific tumor types.
These changes have significantly altered the classical phase
I programs. The studies are more complex and labor-intensive
and tax the resources of many institutions. Phase I studies are
also used earlier in the treatment course and, combined with
their greater efficacy, lead to patients remaining on studies lon-
ger, adding significant coordinator effort. Nevertheless, such
phase I trials may accelerate drug development and enhance
the potential for clinical benefit. The detailed correlative stud-
ies can inform academic and industry research objectives. The
individualized treatment, based on the patient’s tumor biol-
ogy, may lead to an improved therapeutic index and provide
additional opportunities to improve individual clinical out-
comes as well as societal gain. There are >700 new phase I
oncology trials per year [2]. Each costs millions of dollars and
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Commentary
necessitates an organized and efficient clinical research infra-
structure [3].
In this review, we analyze a set of parameters associated
with specific disease types, research sites, patient populations,
and the compound classes that play an important role in the
development of an early phase therapeutics program.We have
explored various factors that can reduce barriers to the estab-
lishment of a successful phase I program in the setting of aca-
demic or community cancer centers. In addition, we offer
recommendations that can enhance the experience of partici-
pating in a phase I program for patients, caregivers, investiga-
tors, institutions, and local communities. Areas that have been
addressed include program organization, personnel, facilities,
regulatory issues, formal meetings, study properties and logis-
tics, patient accrual and enrollment, financial elements, philan-
thropy, and other institutional commitments necessary to
initiate and conduct a successful phase I program. We report
findings from 16 cancer-focused phase I centers—all university-
based. Results from these measurements were compared with
the phase I programs’ outcomes, including number of active
studies, the properties of the studies, and the number of
patients enrolled on different types of studies.
INSTITUTIONS AND METHODS
One- to two-day site visits and/or phone interviews were con-
ducted in 2016 with City of Hope, Johns Hopkins University Sid-
ney Kimmel Comprehensive Cancer Center, University of Texas
San Antonio Cancer Treatment and Research Center, University
of Alabama Birmingham Comprehensive Cancer Center, Holden
Comprehensive Cancer Center at the University of Iowa, Medi-
cal College of Wisconsin Cancer Center, University of Arizona
Cancer Center, University of Michigan Comprehensive Cancer
Center, Massachusetts General Hospital Cancer Center,
Vanderbilt-Ingram Cancer Center, Georgetown Lombardi Com-
prehensive Cancer Center, OHSU Knight Cancer Institute, Uni-
versity of Washington Fred Hutchinson Cancer Research
Center, Washington University School of Medicine Alvin J. Site-
man Cancer Center, Barbara Ann Karmanos Cancer Institute,
and the Harold C. Simmons Comprehensive Cancer Center at
the University of Texas Southwestern.
Each site was analyzed using the metrics in the supplemen-
tal Tables 1–5. For overall organization, we evaluated whether
the phase I program was integrated or separate, whether there
was a designated phase I Director and Associate Director, the
number of phase I principal investigators, and the administra-
tive reporting structure for the phase I staff. Personnel assessed
included the number of phase I dedicated coordinators, regula-
tory and contract personnel, blood and tissue sample handling/
processing/shipping team members, social workers and
financial counselors, investigational pharmacists, administrative
assistants, and budget/financial analysts. For facilities, we
judged whether there was dedicated phase I space and
whether the exam rooms, infusion rooms, pharmacy, pharma-
cology lab, and offices were nearby. Because regulatory issues
can have a significant impact on the success of a phase I pro-
gram, we weighed available phase I standard operating proce-
dures (SOPs)—SOP documents, Data and Safety Monitoring
Committee (DSMC) tolerance for phase I minor deviations, the
presence and number of phase I regulatory staff (particularly
those with U.S. Food and Drug Administration [FDA]
experience), the experience with internal and external audits,
and the opportunity of the phase I director to meet regularly
with the Protocol Review and Monitoring Committee (PRMC),
DSMC, and institutional review board (IRB). Phase I meetings
to review serious adverse events and prioritize trials and
patient accruals were noted, and meeting frequency, member
participation, and meeting location were gauged. In addition,
formal meetings of the phase I director with cancer center lead-
ership and with phase I staff were examined.
The study characteristics were rated, including average
time to study opening, average number of sites per study, num-
ber of hematology and organ-specific trials, number of broad-
spectrum solid tumor trials, number of institutional or investi-
gator Investigational New Drug (IND) documents, and number
of investigator-selected trials (ISTs). Patient issues that facili-
tated study entry were estimated, such as the average time
from patient referral to signed informed consent, presence of
institutional tumor genomic profiling, participation in commu-
nity minority and general outreach talks, institutional marketing
of phase I trials, and available funds for patient travel and
lodging. Financial matters were addressed and included phase I
philanthropy, institutional trial startup costs, institutional over-
head, and maintenance of phase I billing/spreadsheets. The
overall institutional properties and commitment to phase I
were benchmarked by institution patient base, National Cancer
Institute (NCI) funding, philanthropy assistance, basic science
collaborations, and personnel turnover. Finally, we approached
program specialty issues—available Good Manufacturing Prac-
tices facilities, advanced imaging, molecular marker assay, mul-
timodality trials, and presence and nature of assistance in
protocol preparation, such as written guides [4].
The definition of a successful phase I program varies with
the needs of the institution and the community. Rapid access
to a variety of new agents for a large patient population was
regarded as important for most communities and caregivers.
Endpoints included number of trials and patients treated per
year. The addition of novel science and institutional therapy dis-
coveries was ranked highly at academic centers with significant
translational research and/or basic science reputation. End-
pointsmeasured included average number of sites/trial, number
of ISTs, and number of patients treated on ISTs. We embraced
features important for both community and academic medicine
in our rubric.
STATISTICAL ANALYSIS
Characteristics of the cancer center phase I trial programs were
described using descriptive statistics, such as frequency and
percentage for categorical variables, mean and standard devia-
tion for continuous variables with symmetric distribution, and
median and quartiles for continuous variables with skewed
distribution.
RESULTS
Findings are shown in the supplemental online Appendix and
supplemental online Tables 1–5. We masked the identity of
each program and provided information only for the individual
site for the appraisal. Because of the challenges of covering all
the different programs with a single set of metrics, summary
descriptive paragraphs were given. Details of the findings at
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each site are described in the Site Summary Text of the supple-
mental online Appendix.
DISCUSSION
Analysis of multiple successful cancer center phase I programs
revealed surprises regarding organization, personnel, and facili-
ties and anticipated importance of elements in regulatory man-
agement and trial selection. These observations may permit
others to avoid discovery by trial and error.
There were three major methods of site organization—
total, basket, and integrated. The total program had all phase I
studies treating patients with one type of malignancy, patients
with different neoplasms with defined genetic drivers or molec-
ular markers, and patients with any solid tumor or hematologic
malignancy. The basket program left disease-specific phase I tri-
als to disease-oriented teams and only handled studies that
enrolled patients with multiple cancer types. Finally, the inte-
grated programs had no separate phase I personnel. All phase I
work was done with the physicians and personnel of different
disease-oriented teams. If multiple tumor types were eligible
for a study, one disease team managed the protocol and led
the study and activities.
The benefits of a total program were dedicated, experi-
enced personnel and facilities that were best able to address
the regulatory, monitoring, and pharmacologic complexities of
phase I studies. Total programs avoided duplication of early
phase financial, regulatory, and administrative services. The
negative aspects included patient recruitment difficulties. To
recruit patients, the phase I personnel had to approach physi-
cians and patients in various disease-oriented care teams.
Patients may be hesitant to transition to a new physician. There
may be very limited or no routine interaction with the disease-
oriented team or patients pre- and post-study. In addition, there
were extra personnel/facilities costs and discontinuous patient
care.When we began this review, our expectation was that total
phase I programs would have multiple benefits that would
become apparent in terms of trial numbers, patient recruit-
ment, ISTs, and investigator mentoring. With one exception—
site #14—that did not turn out to be the case. Evaluated institu-
tions with basket or integrated phase I programs had more
median phase I trials, phase I patients, phase I ISTs, and dedi-
cated principal investigators (PIs) compared with total phase I
programs. Cancer centers with new or smaller experimental
therapeutics may benefit from trained physician leaders and
staff dedicated to phase IA/IB activities. However, our data sug-
gestedmature and larger phase I programs were highly effective
with the phase I activities managed by individual disease-
oriented teams—particularly with experienced research staff.
Staffing includes screening and treatment coordinators,
data managers, and research nurses. We anticipated that the
long hours and aggressive pace of phase I patient care and data
management would tax the staff and that higher ratios of staff
to trials would be associated with higher patient accruals.
Again, we were surprised to find that was not the case. The
number of trials per coordinator/nurse ranged from 0.9 to 18,
and there was no correlation with total patients accrued. In
fact, the highest enrollments were at sites with a median of 3–
7 trials per coordinator/nurse. Sites #5, #11, #13, and #16 were
outstanding outliers with 6.9, 15, 18, and 12 trials per coordina-
tor/nurse and 89, 304, 173, and 118 enrolled phase I patients
in 2015–2016, respectively. Factors other than numbers had an
impact on productivity. Sites #5, #10, and #11 had direct coordi-
nator/nurse supervision by the physician leader versus a clinical
research organization matrix model. Site #5 physician leader
met to review patients with staff for an hour daily. Sites #4,
#10, and #11 physician leaders met with staff weekly for an
hour. Also, sites #4, #5, and #10 had phase I SOPs in place that
required PIs to provide accurate and timely documentation on
patient visits and lab/x-ray results. Sites #4 and #11 transferred
studies, when they had less acuity in phase IB expansion
cohorts, to disease-oriented teams. This permitted improved
staff efficiencies. Staff retention was variably affected by work-
load. While there was no statistical association between the
number of patients or trials per coordinator and percentage of
staff turnover for the sites overall, the sites with the highest
ratios and available information, sites #5 and #11, did have 70%
and 33% staff turnover, respectively, in 2015. Site #4 doubled
patient accrual in year 2 but had difficulty in recruiting research
coordinators. Several sites had very low personnel turnover
(0%–2%), and these sites had the most experienced phase I
managers. Some programs aggressively recruited and retained
experienced managers and highly qualified staff. Such activities
were needed to avoid “burnout.” Staff at these sites were scien-
tifically engaged by participation in projects and publications
and given salaries and benefits packages that exceed other insti-
tutional and geographic area offers. Site #2 was plagued at first
by high turnover, but instituted a “pod system” that markedly
reduced staff departures. Pods had a screening coordinator, a
treatment coordinator, a data manager, and a laboratory techni-
cian. Each pod handled, on average, eight phase I trials, and all
pod members were familiar with the details of the eight trials.
When individuals were absent due to vacation, illness, site ini-
tiation visits, or investigator meetings, there were other mem-
bers of the pod who could help care for the patients, complete
case report forms (CRFs), participate in teleconferences, and
attend weekly phase I meetings. Four of seven sites used an
acuity index to assign studies so that no single employee had
the majority of complex studies. These indices are algorithms
that quantify coordinator/nurse workload on a study [5].
Although SOPs, structure modifications, and acuity measures
assisted in staff performance, the single most important factor
was the experience and direct supervisory role of the physician
leader and research manager. Site #2 underwent changes dur-
ing the study. Management of personnel was transferred from
a dedicated phase I physician to a core research administrative
team. Regulatory and financial steps were dispersed within the
institution. In the year following these changes, the number of
phase I trials fell from 32 to 13 (56% reduction) and the number
of accrued phase I patients went from 75 per year to 30 per
year (60% reduction). As predicted from leadership studies, the
quality and experience of the physician leaders and clinical
research managers were the most critical factors in program
employee retention and success [6, 7].
Oversight of phase I trials has an important and informative
history [8]. Formalized clinical trials for safety were the conse-
quence of the antifreeze-tainted elixir sulfanilamide and the
Federal Food, Drug, and Cosmetic Act of 1938. Informed
patient consent was the result of the World War II medical
atrocities, resulting in the Nuremberg Code of 1947, the Decla-
ration of Geneva of 1948, the Helsinki Declaration of 1964, and
Frankel, Flaherty,Weiner et al. 371
www.TheOncologist.com Oc 2017 The Authors. The Oncologist published by Wiley Periodicals, Inc.
on behalf of AlphaMed Press
the Kefauver-Harris Amendments to the Food, Drug, and Cos-
metic Act of 1963. The IRB, required for review of patient risks
and benefits in clinical trials, followed the Tuskegee syphilis
study and the Belmont Report of 1979. Finally, Good Clinical
Practice (GCP) guidelines and CRFs were mandated after the
International Conference on Harmonization in 1996 [9].
With this history, institutions have built large infrastructures
to ensure clinical research compliance. For efficient analyses
of phase I protocols, deviations, modifications, and periodic
reviews, close communications between the institutional regu-
latory bodies and PIs is essential. Our survey confirms this. Sites
#3, #4, #6–#10, #12, #14, and #16 had regular meetings with
the PRMC, IRB, and in some cases, the DSMC, and had the
shortest times from protocol submission to patient enrollment.
We cannot emphasize enough the value of an active and fre-
quent dialogue between phase I PIs or physician leaders and
the regulatory bodies. Paper and electronic submissions fail to
yield maximal and timely information exchange. We recognize
the difficulties of this discourse when IRBs handle hundreds of
studies, including many that are phase II–III or not cancer-
related. Two of the three local regulatory bodies, PRMC and
DSMC, have vague mandates. The NCI requires “scientific
review” of trials by the PRMC. The changes suggested by the
PRMC were implemented in 40% of ISTs and 5% of industry
studies [10]. In the end, 97% of industry-sponsored trials and
90% of investigator-sponsored trials were approved by the
PRMC. This again supports early and frequent communication
with the regulatory body. DSMCs have a more diffuse role in
phase I and II trials.With the aid of statisticians and community
members, they address safety and data quality on an ongoing
basis during the study. Industry generates their own DSMCs,
but investigators use the institutional DSMC for ISTs. Details of
their operation are distinct for each organization. Some focus
on safety and others on data quality [11–15]. Available DSMC
plans include those by the National Institute of Dental and
Craniofacial Research (https://www.nidcr.nih.gov/Research/
ToolsforResearchers/Toolkit/DSMBGuidelines.htm), and the
University of Oregon, the University of Wisconsin, and the
Dana-Farber Cancer Institute, among others (https://cancer-
centers.cancer.gov/). Because each institution’s DSMC has its
own priorities, again, close communication and cooperation
between the phase I physician leader, phase I manager, phase I
quality assurance personnel, and DSMC is vital. DSMCs can
place studies on hold for safety or data quality. In fact, the
DSMCs of 4 of the 16 sites permit no deviations from protocol
(sites #2, #7, #8, #11, and #12), whereas the other 12 of the 16
sites evaluate deviations on a case-by-case basis. Deviations
triggered a protocol hold only at site #2. A fourth regulatory
oversight body is the FDA. Investigator-initiated or -sponsored
trials require IND submissions and FDA notification of serious
adverse events (SAEs) within 15 days, according to the Code of
Federal Regulations 21.312.32. IST PIs and phase I regulatory
personnel must be aware of their federally mandated obliga-
tion to notify the FDA promptly. All the regulatory issues in
phase I can be summarized in one word—communication.
Nevertheless, for all sites, delays in trial activation were the
most consistent and strong theme to emerge from this review.
Barriers were multifactorial but likely augmented by large and
often redundant regulatory bodies [16]. Published data indicate
that longer time to trial activation is associated with lower
patient enrollment [17]. At site #9, a fast-track program was
developed that reduced study initiation time from 163 days to
45 days [18]. Site #4 embedded dedicated financial, regulatory,
and grants/contract officers to improve trial activation times.
Site #2 went in the opposite direction with transfer of manage-
ment, regulatory, and financial matters to activities outside the
phase I program, leading to a prolongation of study activation
time from a median of 5 months to greater than 12 months
and a two-thirds reduction in phase I trials and accrued
patients in the next year. Sites #9 and #14 had the shortest
startup times and the most phase I trials and ISTs and IST
patients accrued and were among the top three sites for overall
phase I patient accrual. Thus, we strongly believe GCP and insti-
tutional compliance can be maintained with a smaller, stream-
lined bureaucracy and such institutional changes will positively
impact phase I programs.
Study content is the “meat” of a phase I program.We iden-
tified four types of phase I trials—phase IA, phase IB, phase I
trials with institutional correlative science, and ISTs. Phase IA
trials are first-in-human dose-escalation studies. Phase IB trials
expand the number of patients treated at the MTD in a novel
disease cohort or combine the drug with a second therapy in a
limited dose-escalation schema. Correlative science phase I tri-
als use institutional experimental laboratory or imaging bio-
markers. ISTs are based on investigator science or clinical
research and may use locally generated agents. There is often
an evolution of trials at sites. New programs are often selected
to participate in phase IB studies. Physician leaders and PIs can
make connections to the pharmaceutical/biotechnology indus-
try or contract research organizations to gain access to these
studies. The phase IB trials typically have multiple sites and
reduced PK assays and SAEs. The study may be an expansion in
particular diseases based on phase IA or pharmacogenomics.
Most consist of pathway inhibitors or immune checkpoint mod-
ulators in disease subsets or combinations of pathway inhibi-
tors or immune checkpoint modulators with members of the
same therapeutic class or other agents. Sites #3, #4, #6–#13,
#15, and #16 had many of these studies and had excellent
patient accruals. Sites #2, #6, #7, #10, and #15 are relatively
new phase I programs and have benefited from this class of
clinical study. Retrospective analyses of patients treated on pri-
marily phase IB studies for gastrointestinal cancer and lung can-
cer showed response rate (RR) of 4% and 16% and stable
disease of 38% and 41%, respectively [19, 20]. Further, in
genomically matched patients, phase I trials yielded a RR of
27% [21]. Hence, this class of phase I investigation benefits
both the institution and patients. In fact, clinical genomics
yielded actionable DNA alterations in 89% of prostate cancer
patients in one cohort of 150 patients [22]. Phase IB trial selec-
tion based on genomics is feasible. Phase IA or first-in-human
studies are more commonly performed at private practice
phase I units due to speed of activation, patient volumes,
and experience. They have more pharmacokinetics and phar-
macodynamics and toxicity reporting. Nevertheless, several
first-in-human trials were performed at some cancer center
sites. Site #3 had a large PK laboratory. Site #2 had PI expertise
in a particular therapeutic class. Because of their small patient
volumes, their main attraction is their novelty. By participating
in phase IA, if the biological activity is promising, the site is well
positioned for further studies. Phase I studies with institutional
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correlative science are very attractive for institutions with a
large basic and translational science expertise. Site #2 used
advanced magnetic resonance imaging (MRI) imaging in trials
testing onco-metabolite and transcription factor inhibitors. Site
#4 had access to a molecular imaging core facility with a cyclo-
tron and positron emission tomography/MRI. Site #11 also
used advanced MRI and ultrasound imaging to quantify
changes in tumor perfusion as part of the phase IB studies. Site
#13 performed clinical genomics prospectively on pretreatment
tumor samples, which permits early identification of bio-
markers. Site #14 offered serial tumor biopsies and rapid
autopsies. Site #16 had many immunological assays. The
requirements to perform such studies include reagent support
from industry and philanthropic or grant support from the
institution.
ISTs represent the pinnacle of cancer center discovery and
advancement. These have the greatest opportunity for mentor-
ing clinical investigators. Sites #1-–#3, #9, #14, and #16 had the
most ISTs and the highest ratio of IST/all phase I trials. In prior
years, the ISTs at these sites led to first or senior author presen-
tations at the American Society of Clinical Oncology and publi-
cation of journal articles. Patients benefited from the PI insights
and the partnerships between biotech/pharma and the cancer
center.
Patient accrual on trials is challenging both for getting
referrals and for consent and eligibility. Navigators are
extremely valuable in increasing referrals, as shown at sites
#1, #3, #4, #8, #10, #11, and #14. A large patient base—
17,000 new cancer patients in 2015—aided referrals for site
#6. Screen failures are common and occur due to cancer pro-
gression during the screening period and/or poor perform-
ance status [23]. The Royal Marsden Hospital prognostic
score has been validated by an MD Anderson Cancer Center
phase I clinic [24, 25]. Multiple relapsed patients also do
more poorly on phase I studies [26]. In contrast, patients with
cardiac ejection fraction >35%, modest renal dysfunction, or
elderly healthy patients do well on phase I trials [27–29].
Patient refusal is another barrier—African Americans and Lat-
inos are two- and three-fold more likely to decline phase I
study enrollment, respectively [30, 31]. A minority recruit-
ment plan has been initiated at two of our phase I sites [32,
33]. Most patients lack understanding of the intent of phase I
trials [34]. In addition, many oncologists do not refer patients
for phase I trials due to perceived lack of clinical benefit and
costs in physician time and resources [35]. In light of this het-
erogeneity, navigators, community and physician education
outreach, cooperative group physician referral minima, and
adequate patient informed consent are important and wor-
thy of the time, resources, and effort [36, 37]. One site added
prescreening, frequent communications with patients, dedi-
cated staff to interact with insurance providers, and social
media/patient advocacy group engagement to enhance trial
accrual [18]. Phase I trial patient enrollment is the single
most challenging aspect of phase I program growth.
Our review did not address private U.S. phase I centers and
international academic phase I programs. We approached two
private phase I businesses, but neither was willing to provide
infrastructure information. Many of the challenges observed in
academic centers may be streamlined in non-university envi-
ronments, but the role of ISTs and pharmacodynamics studies
may be more difficult without institutional basic science. Inter-
national academic centers were not studied due to cost and
time constraints but merit evaluation and comparison. Govin-
dan and colleagues compared various oncology clinical research
parameters between Washington University of St. Louis (one of
our sites) and the University of Torino, Italy [38]. The median
time to trial opening and median number of patients accrued
per study was 5.5 months and 7.4 patients, respectively, for the
U.S. university versus 3.7 months and 37 patients, respectively,
for the Italian university. Their analysis found multiple addi-
tional steps and longer time to activate trials in the U.S. In addi-
tion, insurance denials reduced patient accruals in the U.S. but
not in Europe, with socialized medicine. Future detailed studies
are warranted to learn from U.S. private and European aca-
demic phase I programs.
CONCLUSION
Phase I programs merit careful consideration of size and expan-
sion goals and endpoints. Based on the nature of the institution
and community and local physician networks, there are multi-
ple choices. Cancer centers serving large populations with large
private practice oncology groups may be served best by phase
IB studies yielding enhanced safety and some efficacy and a
more robust trial portfolio. Cancer centers with an active
pharmacology department are ideal sites for phase IA and cor-
relative science experiments [39–42]. Basic research-rich uni-
versities and translational research centers may focus on ISTs
and institutional INDs. Finally, new phase I programs may pro-
gress from phase IB to phase IA/correlative science studies
toward ISTs over time as more resources are available and as
the site’s reputation grows. The logistical support to achieve
high-quality care and research is a tremendous undertaking
and must address management, personnel, regulatory, patient
education, and navigation [43, 44]. In summary, we strongly
believe the complex efforts for phase I programs are worth nur-
turing, provide an outstanding service to cancer patients, can
lead to improved human health, and can lead to advancements
in science in many cancer centers.
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